SB-207 is under clinical development by Pelthos Therapeutics and currently in Phase II for Genital Warts (Condylomata Acuminata). According to GlobalData, Phase II drugs for Genital Warts (Condylomata Acuminata) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SB-207’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SB-207 overview
Berdazimer sodium is under development for the treatment of external genital warts. It is a nitric oxide-releasing macromolecule. It was administered through topical route. The drug candidate was developed based on Nitricil technology.
Pelthos Therapeutics overview
Pelthos Therapeutics is a biopharmaceutical company focus on developing therapeutic products for dermatological conditions and patients with unmet treatment burdens. The company is headquartered in Durham, North Carolina, the US.
For a complete picture of SB-207’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
